PMID- 20813688
OWN - NLM
STAT- MEDLINE
DCOM- 20130624
LR  - 20151119
IS  - 1673-4254 (Print)
IS  - 1673-4254 (Linking)
VI  - 30
IP  - 8
DP  - 2010 Aug
TI  - [Dynamic observations of beta-catenin in chronic myeloid leukemia and its 
      relationship with cytogenetic response].
PG  - 1868-70, 1873
AB  - OBJECTIVE: To investigate the changes in the expression of beta-catenin in 
      patients with chronic myeloid leukemia (CML) in different phases, and explore the 
      relationship between beta-catenin and the cytogenetic response to imatinib 
      mesylate. METHODS: Beta-catenin mRNA and protein expressions were detected by 
      RT-PCR and Western blotting in the bone marrow mononuclear cells (BMMNCs) from 99 
      CML patients. The expressions of BCR-ABL fusion gene at both the mRNA and protein 
      levels were detected by fluorescence in situ hybridization (FISH) in 94 patients 
      before and during the one-year treatment with imatinib mesylate at the interval 
      of 3 months, and the relationship between beta-catenin and cytogenetic response 
      to imatinib mesylate was analyzed. RESULTS: The expression of beta-catenin 
      increased significantly in patients with blast crisis and accelerated phase 
      (P<0.001), but showed no significant difference between normal subjects and CML 
      patients in the chronic phase (P>0.05). The main cytogenetic remission rate was 
      significantly higher in patients who were consistently negative for beta-catenin 
      than in those consistently positive for beta-catenin or those with a positive 
      transformation (P<0.001). CONCLUSION: Beta-catenin overexpression in the 
      progression of CML, consistent high level of beta-catenin or a positive 
      transformation may indicate a poor response to imatinib, and early measures 
      should be taken to increase the remission rate.
FAU - Zou, Wai-yi
AU  - Zou WY
AD  - Department of Hematology, First Affiliated Hospital of Sun Yat-sen University, 
      Guangzhou 510080, China. waiyizou@medmail.com.cn
FAU - Xu, Duo-rong
AU  - Xu DR
FAU - Su, Chang
AU  - Su C
FAU - Chen, Mei
AU  - Chen M
FAU - Li, Juan
AU  - Li J
FAU - Luo, Shao-kai
AU  - Luo SK
LA  - chi
PT  - English Abstract
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - China
TA  - Nan Fang Yi Ke Da Xue Xue Bao
JT  - Nan fang yi ke da xue xue bao = Journal of Southern Medical University
JID - 101266132
RN  - 0 (Benzamides)
RN  - 0 (CTNNB1 protein, human)
RN  - 0 (Piperazines)
RN  - 0 (Pyrimidines)
RN  - 0 (RNA, Messenger)
RN  - 0 (beta Catenin)
RN  - 8A1O1M485B (Imatinib Mesylate)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Benzamides/therapeutic use
MH  - Blast Crisis/drug therapy/genetics/metabolism
MH  - Case-Control Studies
MH  - Female
MH  - Humans
MH  - Imatinib Mesylate
MH  - Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug 
      therapy/*genetics/*metabolism/pathology
MH  - Male
MH  - Middle Aged
MH  - Piperazines/therapeutic use
MH  - Pyrimidines/therapeutic use
MH  - RNA, Messenger/genetics
MH  - Young Adult
MH  - beta Catenin/*metabolism
EDAT- 2010/09/04 06:00
MHDA- 2013/06/26 06:00
CRDT- 2010/09/04 06:00
PHST- 2010/09/04 06:00 [entrez]
PHST- 2010/09/04 06:00 [pubmed]
PHST- 2013/06/26 06:00 [medline]
PST - ppublish
SO  - Nan Fang Yi Ke Da Xue Xue Bao. 2010 Aug;30(8):1868-70, 1873.